Clinical assessment of oral mucositis and candidiasis compare to chemotherapic nadir in transplanted patients
AUTOR(ES)
Cleverson, PATUSSI, Laurindo Moacir, SASSI, Eduardo Ciliao, MUNHOZ, Roberta Targa Stramandinoli, ZANICOTTI, Juliana Lucena, SCHUSSEL
FONTE
Braz. oral res.
DATA DE PUBLICAÇÃO
2014
RESUMO
Oral mucositis is a chief complication in patients undergoing hematopoietic stem cell transplantation (HSCT). It is considered a toxic inflammatory reaction that interferes with the patient’s recuperation and quality of life. Oral candidiasis is a common fungal infection observed in dental practice, particularly in immunocompromised patients. The aim of this study was to evaluate the presence of oral mucositis and oral candidiasis in patients who underwent HSCT and their correlation with the chemotherapeutic nadir (lowest possible outcome). We evaluated patients with different diagnoses who underwent HSCT at the Hospital Erasto Gaertner. No chemotherapeutic nadir curves could be associated with mucositis, and patients had different presentations of mucositis. No patient developed oral candidiasis during hospitalization. Together with cell counts, we collected demographic data including age, oral hygiene, habits harmful to health, and the use of oral prostheses. It was observed that patients who smoked cigarettes before hospitalization showed less mucositis, resulting in no feeding problems or other comorbid conditions due to the effect of mucositis. However, the nadir of the chemotherapy curve, in isolation, is not a predictive tool for the appearance (or no appearance) of oral mucositis.
Documentos Relacionados
- Clinical and laboratorial features of oral candidiasis in HIV-positive patients
- Oral Mucositis in Pediatric Oncology Patients: A Nested Case-Control to a Prospective Cohort
- Efficacy of low-level laser therapy and aluminum hydroxide in patients with chemotherapy and radiotherapy-induced oral mucositis
- Oral candidiasis in HIV+ patients under treatment with protease inhibitors
- Conventional and alternative antifungal therapies to oral candidiasis